期刊文献+

糖尿病新药依帕列净的药理作用及临床评价 被引量:1

原文传递
导出
摘要 新型钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂依帕列净(empagliflozin,商品名Jardiance)是由勃林格殷格翰制药公司和礼来公司联合开发的一种降糖药物。相比于其他SGLT2抑制剂,依帕列净对SGLT2的抑制作用具有高度选择性,而且胃肠道耐受性较好。其化学名称是(1S)-1,5-脱水-1-C-(4-氯-3-((4-(((3S)-四氢-3-呋喃基)氧基)苯基)甲基).
机构地区 河南省人民医院
出处 《中国药学杂志》 CAS CSCD 北大核心 2016年第7期598-600,共3页 Chinese Pharmaceutical Journal
  • 相关文献

参考文献17

  • 1MARSENIC O. Glucose control by the kidney: an emerging tar- gent in disabetes [ J ]. Am J Kidney Dis, 2009,53 ( 5 ) : 875-883.
  • 2BASILE J. A new approach to glues control in type 2 disabets: the role of kidey sodium-glucose contransporter 2 inhibition [ J ]. Postgard Med, 2011, 123(4) :38-45.
  • 3NEUMILLER J J, WHITE J R, caMPBELL R K. Sodium glucose co-transport inhibitiors: progress and therapeutic potential in type 2 disabets mellitus [ J]. Drugs, 2010, 70(4) :377-385.
  • 4NAIR S, WILDING J P. Soidum glucose cotransporter 2 inhibi- tiors as a new treatment for diabetes mellitus [ J ]. J Clin Endocri- nol Metab, 2010, 95(1):34-42.
  • 5MENG W, ELLSWORTH B A, NIRSCHI A A, et al. Discovery of adpagliflozin: a potent, selective renal sodium-dependent glu-.cose cotransporter2 (SGLT2) inhibitor for the trentment of type 2 diabets [ J ]. J Med Chen, 2008, 51 ( 5 ) : 1145-1149.
  • 6LUIPPOLD G, KLEIN T, MARK M, et al. Empagliflozin, a no- vel potem and selective SGLT-2 inhibitior, improves glycaemic control alone and in combination with insulin in streptozotocin-in- duced diabetic rats, a model of type 1 disabetes mellitus [ J ]. Di- abets Obes Metab , 2012, 14(7) :601-607.
  • 7FERRANNINI E, SEMAN L, EEWALDT-BECKER E, et aL A phase lib, randomized, placebo-controlled study of the SGLT2 in- hibitior empagliflozin in patients with type 2 disabets [ J ]. Dia- bets, Obes Metab, 2013, 15(8) :721-728.
  • 8RIGGS M M, STAAB A, SEMAN L, et al. Population pharmaco- kinetics of empagliflozin, a sodium glucose cotransporter 2 inhibi- tor, in patients with type 2 disabetes [ J ]. J Clin Pharmacol, 2013, 53 (10) : 1028-1038.
  • 9LIU Y, SHI S, WU J, et al. Safety, tolerability , pharmacokinet- ics and pharmacodynamics of recombinant human parathyroid hor- mone after single and multiple-dose subcutaneous administration in healthy Chinese volunteers [ J 1. Basic Clin Pharma~ol Toxicol, 2012,110(2) :154-161.
  • 10CAHN A, TAL-SINGER R, POULIQUEN I J, et al. Safety, tol- erability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy and subjects : two randomized studies [ J ~. Clin Drug Invest, 2013, 33 ( 7 ) : 477- 488.

同被引文献2

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部